Insulin News and Research

RSS

Insulin is a hormone that is needed to convert glucose, starches and other food into energy needed for daily life. Insulin allows cells to use glucose for fuel and is secreted by beta cells in the islets of Langerhans. The release of insulin from the pancreas is stimulated by increased blood glucose, vagal nerve stimulation, and other factors. Insulin is obtained from various animals and available in a variety of preparations. Commercial insulin preparations differ in a number of ways, including differences in the animal species from which they are obtained; their purity, concentration, and solubility; and the time of onset and duration of their biologic action. An oral hypoglycemic agent is not a form of insulin therapy.

Combination of exercise and metformin less effective for people with diabetes

It's common enough for researchers to look at the impacts of prescribed drugs on the body. And if you're a diabetes researcher who believes that exercise has great benefits for those with type 2 diabetes, you're hoping your research will show that. But when Normand Boul- looked at the dual impacts of exercise and metformin - two of the most commonly-prescribed modalities for glucose control - on that very outcome, the hoped-for double whammy wasn't the result.

20 Aug 2011

BTI completes SUGARDOWN human clinical study on blood sugar management

Boston Therapeutics, Inc. (BTI), a public company registered with the SEC and a developer of diabetes therapeutics, announced today the completion of a trial in healthy volunteers performed at the University of Sydney on SUGARDOWN, a dietary supplement designed to reduce post-meal elevation of blood glucose.

18 Aug 2011

IU scientist to investigate salubrinal drug against osteoporosis

An Indiana University scientist studying human bone growth has received a $2.6 million grant from the U.S. Department of Defense to study a chemical compound with potential to fight osteoporosis and accelerate broken bone healing.

18 Aug 2011

Green tea shows promise against two types of tumors, HHS

A compound found in green tea shows great promise for the development of drugs to treat two types of tumors and a deadly congenital disease. The discovery is the result of research led by Principal Investigator, Dr. Thomas Smith at The Donald Danforth Plant Science Center and his colleagues at The Children's Hospital of Philadelphia.

16 Aug 2011

New pathway for type 2 diabetes

Newly diagnosed type 2 diabetics tend to have one thing in common: obesity. Exactly how diet and obesity trigger diabetes has long been the subject of intense scientific research.

16 Aug 2011

Research: Decoding infidelity may increase risk of type 2 diabetes

Type 2 diabetes is an extremely common chronic condition characterized by high levels of sugar in the blood as a result of either insufficient production of the hormone insulin or an inability of cells to respond to insulin.

16 Aug 2011

Fat interferes with body's sugar sensors to trigger type 2 diabetes

Researchers from the United States have identified how a high-fat diet can trigger type 2 diabetes, in experiments on mice and human tissue. They reveal in their study published in the journal Nature Medicine that fat interferes with the body's sugar sensors. The authors add that deeper understanding of the processes involved could help them develop a cure.

15 Aug 2011

CPAP withdrawal leads to return of obstructive sleep apnea

The benefits of continuous positive airway pressure machines (CPAP) for patients with obstructive sleep apnea (OSA) are quickly reversed when the therapy is withdrawn, according to Swiss research.

12 Aug 2011

Spices may reduce oxidative stress and risk of chronic disease

Eating a diet rich in spices, like turmeric and cinnamon, reduces the body's negative responses to eating high-fat meals, according to Penn State researchers.

11 Aug 2011

Nesfatin-1 protein may help reduce body weight and blood sugar

A newly-identified protein may hold the key to keeping appetite and blood sugar in check, according to a study by York University researchers.

10 Aug 2011

Medications can be harmed by excessive heat

We all know that people and animals can be harmed by excessive heat; so can medications, states Dr. Amy Peak, director of Drug Information Services for Butler University.

10 Aug 2011

Pre-emptive insulin therapy reduces risk of diabetes mellitus after kidney transplantation

Up to 30 percent of all patients develop diabetes mellitus within the first year after a kidney transplantation. This high rate could soon fall rapidly. A Medical University of Vienna research team at Vienna General Hospital's University Department of Internal Medicine III has discovered in the context of a study that pre-emptive insulin therapy drastically reduces this rate.

8 Aug 2011

Insulin pumps and other medical devices ‘hackable’

A diabetic security researcher has identified flaws that could allow an attacker to remotely control insulin pumps and alter the readouts of blood-sugar monitors. As a result, diabetics could get too much or too little insulin, a hormone they need for proper metabolism.

5 Aug 2011

Virginia Tech student receives prestigious award for cellular signaling receptor study linked to diabetes, obesity

Stephanie Nicole "Nikki" Lewis, a graduate student in the interdisciplinary doctoral program in genetics, bioinformatics, and computational biology at Virginia Tech, has been awarded the prestigious Ruth L. Kirschstein National Research Service Award for Predoctoral Research through the National Institutes of Health for her study of a cellular signaling receptor that is associated with chronic inflammatory diseases such as diabetes, obesity, and inflammatory bowel disease.

5 Aug 2011

FDA grants Orphan Drug Designation to Kamada's AAT product for type 1 diabetes

Kamada LTD., a bio-pharmaceutical company engaged in the development, manufacturing and marketing of specialty life-saving therapeutics, was granted an Orphan Drug Designation for its Alpha-1 Antitrypsin (AAT) product to treat type 1 diabetes.

5 Aug 2011

Boston Therapeutics files chewable metformin ANDA with FDA to treat diabetes

Boston Therapeutics, Inc., a public company registered with the SEC and a developer of diabetes therapeutics, today announced that it has submitted an Abbreviated New Drug Application (ANDA) for chewable metformin with the U.S. Food and Drug Administration.

4 Aug 2011